Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thats only 138 miles from my house. May have to attend.
Bruker AXS Announces Gulf Coast Petrochemical Seminar July 17 in The Woodlands, Texas
As part of Bruker AXS' commitment to foster professional advancement for petrochemistry industry analysts, improve proficiency, reduce cost and enhance quality, Bruker AXS invites petrochemistry industry personnel to attend its FREE Bruker Gulf Coast Pet
(EMAILWIRE.COM, June 25, 2008 ) Madison, Wisc.—June 24, 2008—Bruker AXS today announced a free full-day advanced petrochemical seminar to take place July 17 in The Woodlands, Texas. Attendees will learn how to keep production up to satisfy high demand as oil prices soar, while regulatory compliance mandates ultra low sulfur content, especially in diesel and biodiesel.
How will YOUR lab comply?
As part of our commitment to foster professional advancement for analysts, improve proficiency, reduce cost and enhance quality, Bruker AXS invites you to attend our FREE Bruker Gulf Coast Petrochemical Seminar on Thursday, July 17, 2008. Join us at Bruker in The Woodlands, TX to learn about X-ray Fluorescence (XRF) spectrometry and how it applies to your work. Hear presentations by Peter Eversley, Charles Taylor, Bernie Squires and other industry professionals as they share their firsthand knowledge and application experiences using XRF in the petrochemical arena.
You will learn about the technology enabling the WD XRF analysis of sulfur to cover more and more matrices and reach ultra low levels. We will show how to increase performance by employing the right tools and procedures. We’ll give you tips on what YOU can do in YOUR lab to achieve better LLD’s and accuracy!
Reviewing and understanding the new draft for the ASTM 2622 procedure covering ULS will enable all participants to be prepared for the challenges ahead. Larry Arias, ASTM D committee member, will answer YOUR questions and explain the new qualification approach.
How is XRF used at BP and LyondellBasell?
These real world case studies also include a presentation of the Consortium of Refineries (COR) initiative for proficiency testing. Are you analyzing correctly? What is your benchmark? How do YOU compare with others? All questions which can be answered if you take part in the COR round robin tests.
Ever wondered what needs to be done to get the oil into the refinery?
From exploration and drilling to production and engineering, Hughes Christensen Central Analytical Facility uses XRF to support the global business of getting the oil out of the ground! A tour of the drill and analytical facility is complemented with the practical application of Standardless e.g. universal quantification in a VERY diverse application field.
The days’ schedule will allow open lab time to explore the Bruker Woodlands facility, as well as ample time to network. Lunch is included. The off-site tour requires registration by July 10, as well as a photo ID. Non-US citizens need proof of residency and passport. No exceptions. Transportation provided. All registrants receive a participation certificate and seminar materials
This event will fill up fast, and seats are limited – register today!
About Bruker AXS
Bruker AXS is a leading developer and provider of life science, materials research, and industrial X-ray analysis, spark-OES and combustion analysis tools. For more information, please visit www.bruker-axs.com
http://www.emailwire.com/release/14353-Bruker-AXS-Announces-Gulf-Coast-Petrochemical-Seminar-July-17-in-The-Woodlands-Texas.html
Nice BIG Bounce..... more like KRAIGGER.... NICE WORK ON THAT PICK UP BUDDY....
GO GREEN TEAM!!!
Nice little bounce were getting, Slow and Steady wins the race.
European High Temperature Superconductors (EHTS) Receives Research Grant from German Government for Advanced Copper-HTS Conductors
Thursday June 12, 6:00 am ET
HANAU, Germany--(BUSINESS WIRE)--European High Temperature Superconductors GmbH & Co. KG (EHTS), a division of Bruker Corporation’s Advanced Supercon business, announced this week that the German Federal Ministry of Commerce and Technology (BMWi) has approved a grant for a joint $3.0 million research project with Adelwitz Technologiezentrum (ATZ) in Arzberg, Germany. The three-year project for the development of advanced commercial superconductors is based on EHTS’ proprietary second generation YBCO wire technologies. EHTS expects to be reimbursed about $0.74 million (€0.48 million) under the grant for its approximately $1.5 million share of the overall project budget.
The funding to EHTS and ATZ has been granted within the framework of the German government’s technology initiative to meet the national and European goals for significant reductions in energy consumption and carbon emissions by the year 2020. High temperature superconductors (HTS) transport electricity virtually without losses, thus reducing energy consumption across many technology areas. Large machines and equipment used for propulsion, power generation, transmission and power grid protection are ideal applications for HTS conductors, allowing these devices to be smaller and more energy efficient.
The project partners will develop advanced copper-HTS hybrid superconductors that can operate reliably under a wide range of demanding conditions and provide unprecedented protection under mechanical stresses and electrical fault conditions. The cooperation between EHTS and ATZ, which has been ongoing since 2005, has achieved several milestones in the development of advanced 2G conductors with copper shunts, including conductors that carry current upwards of 500 Amperes per cm width.
“EHTS has outstanding research expertise in the development and manufacturing scale-up of 1G and 2G high-temperature superconductors,” said Dr. Burkhard Prause, Managing Director of EHTS. “Our 2G Copper-HTS hybrid conductor has world-leading electro-mechanical properties. We are very pleased and delighted to receive this grant, together with ATZ, for the further development of commercial conductors and production processes. It is a confirmation of our technology development program and the successful cooperation with ATZ.”
About EHTS/Advanced Supercon:
European High Temperature Superconductors GmbH & Co. KG is based in Alzenau, Germany and is part of the Advanced Supercon business of Bruker Corporation (NASDAQ: BRKR - News). In addition to EHTS, the Advanced Supercon business also includes European Advanced Superconductors (EAS) in Germany, Hydrostatic Extrusions Limited in Scotland, and Advanced Supercon, Inc. in the United States. EHTS is a leading manufacturer of HTS materials and devices, based on its broad HTS technology platform. EHTS solutions enhance the reliability and efficiency of electrical power grids and large energy demanding applications. Its proprietary SuperFast™ superconducting fault current limiter (SFCL) concept has the potential to enhance power grid reliability, and its HTS current lead products dramatically reduce electrical losses in large industrial and research magnets. Conductors and components made by EHTS are being used to build a new generation of compact high power devices such as HTS motors, generators, cables and transformers as well as high field magnets for medical and research applications. For more information: www.bruker-ehts.com
About ATZ: Founded in 1992, Adelwitz Technologiezentrum GmbH (ATZ) is a technology company offering a wide spectrum of High-Tc superconducting materials and innovative components. The company’s business is based on HTS powder, bulk and target materials, as well as components and solutions for magnetic bearings and systems, flywheels, power engineering, periphery for conductor development and cryostats. ATZ’s HTS products address today’s energy conservation challenges. One core technology is HTS magnetic bearings up to ton loads, as it is presently assembled in a 10 kW /280 kW flywheel. ATZ’s technologies are protected by intellectual property ranging from bulk materials up to surface copper plating on HTS wires and tapes. For more information: www.atz-gmbh.com
Contact:
Burkhard Prause, Ph.D., +49 (0)6181 4384-4133
Managing Director, EAS and EHTS
Burkhard.Prause@advancedsupercon.com
or
Tom Rosa, 1-978-901-7550
CFO and Senior VP
Advanced Supercon, Inc. (ASCI)
tom.rosa@asci.bruker.com
Chmn Laukien buys 50,000 of Bruker Corp. BRKR
SOURCE: Form 4
ISSUER: BRUKER CORP
SYMBOL: BRKR
FILER: LAUKIEN FRANK H
TITLE: Chairman of the Board
DATE TRANSACTION SHARES PRICE VALUE
6/9/08 Purchase 50,000 $11.60 $579,755
OWNERSHIP: 36,454,445 (Direct)
The Form 4 is filed with the Securities and Exchange Commission by insiders
to report transactions in their companies' shares. Open market purchases
and sales must be reported within two business days of the transaction.
BRKR CHART Sure looks like it is ready to Bounce
Looking Good MSC....
Liking in news....BRKR is a great company w/ strong demand and great tech..... ...GL
Cheers, Hope you have and are having a great day....Good Luck and TTYS
JT
(technically, looking for a nice 'lil DI+- cross)
European Advanced Superconductors, a Division of Bruker's Advanced Supercon Business, Reports Record Current with Powder-In-Tube Superconductor
HANAU, Germany (Business Wire EON) May 21, 2008 -- A new record value of critical current in its Nb3Sn superconductors has been reached by European Advanced Superconductors GmbH & Co. KG (EAS) using the company’s proprietary Powder In Tube (PIT) technology, the Advanced Supercon business of Bruker Corporation announced today.
At a magnetic field of 12 T and a temperature of 4.2 K, the proprietary PIT conductor achieved a record non-copper current of 2,634 A/mm2, approximately 5% higher than previous records. EAS acquired the PIT technology from the Dutch company SMI in December of 2006 and has continued to develop these very high current Nb3Sn conductors for a range of applications, including future fusion projects.
The new record PIT conductor is 1.25 mm in total diameter and consists of 288 superconducting filaments with each being less than 50 micrometers in diameter. This special type of superconductor is being developed for the Next European Dipole (NEP) programme at CERN in Geneva, Switzerland.
“We have been a partner for CERN in their accelerator projects for many years now and are very pleased to present this outstanding result in time for CERN’s biannual review of superconductor and magnet design, which we are currently attending in Geneva,” stated Reinhard Dietrich, Sales and Marketing Director of EAS. “The most recent example of our project work with CERN is the Large Hadron Collider (LHC), for which we delivered NbTi-superconductor cables for dipoles, quadropoles and detector magnets. With this latest improvement in our very high current PIT conductors, we have further strengthened our position as an innovation leader in superconducting materials, in particular for future needs in high energy physics and fusion research projects.”
About EAS/Advanced Supercon:
European Advanced Superconductors GmbH & Co. KG is based in Hanau, Germany and is part of the Advanced Supercon business of Bruker Corporation. In addition to EAS, the Advanced Supercon business also includes European High Temperature Superconductors (EHTS) in Germany, Hydrostatic Extrusions Limited in Scotland, and Advanced Supercon, Inc. in the United States. EAS is a world leading manufacturer of high performance superconductors used for clinical MRI, scientific instruments including NMR, EPR, and FTMS, as well as for large-scale research applications in high energy physics and fusion projects. For more information, please visit our website at www.advancedsupercon.com
http://www.emediawire.com/releases/advanced/superconductor/prweb963454.htm
Bruker BioSciences Corp. (BRKR): CEO, President, Director, 10% Owner Frank H Laukien Bought 150,000 Shares
Bruker Corporation (BRKR) provides x-ray and molecular analysis products. The company anticipates $12 million loss or $0.06 per share loss from the weakened dollar and foreign currency. Bruker expects revenue of $235 to $240 for the first quarter.
CEO, President, Director, 10% Owner Frank H. Laukien bought a total of 150,000 shares of BRKR stock on 5/7/08 around $12.10.
Bruker BioSciences Corp. has a market cap of $2.03 billion; its shares were traded at around $12.52 with a P/E ratio of 80.77 and P/S ratio of 3.50.
http://www.gurufocus.com/news.php?id=27470
Thanks for the news Friend....
I like this stock now....will grab another block today if the market looks good...
Bruker BioSciences "equal weight," target price raised
3:16 p.m. - Lehman Brothers
NEW YORK, April 15 (newratings.com) - Analyst Anthony Butler of Lehman Brothers maintains his "equal weight" rating on Bruker BioSciences Corporation (BRKR), while raising his estimates for the company. The target price has been raised from $15 to $16.
In a research note published this morning, the analyst mentions that the company is likely to post its 1Q total revenues and GAAP EPS at $233.8 million and $0.10, respectively. The Life Science Technology and Diagnostic companies might outperform the S&P 500 Index in the March quarter, the analyst adds. The EPS estimate for FY08 has been raised from $0.53 to $0.57.
http://www.newratings.com/en/main/company_headline.m?id=1729703
Hey TM....
Nice to have you here at the NEW ASSIST MOD....word up and cheers!.....
Thanks for your help and your time.....
I am sure you will come to like BRKR ....great technology with ever expanding horizons....
Thanks again for joining the team and Good Luck to you always,
JT
(expecting BRKR to continue its retrace...perhaps close the gap at 12.22 in 2 / 27 OR the gap on 3 / 17 @ 14.18 (should close Monday unless the market are crazy green for some unknown reason....)
http://finance.yahoo.com/echarts?s=BRKR#chart4:symbol=brkr;range=3m;indicator=volume;charttype=candlestick;crosshair=on;ohlcvalues=0;logscale=off;source=undefined
Hey JT
I'll be checking this one out a little more this weekend :)
yes, now a slight pull-back appears to be coming in smoothly...
ttys Friend and GL,
JT
Bruker Corp. shares hit 6-yr high; UBS reiterates buy rating, $15 price target
February 28, 2008: 10:12 AM EST
BOSTON, Feb. 28, 2008 (Thomson Financial delivered by Newstex) -- Shares of Bruker Corp. rallied Thursday after the Billerica, Mass.-based manufacturer of analytical and life science systems reported stronger-than-expected fourth-quarter earnings and revenue results.
The stock climbed as high as $13.73, a six-year high, before paring some of its gains to change hands at $13.65, up 12% intraday on volume of 745,000. The issue's 30-day average volume is 485,000.
Prior to the market open, Bruker reported fourth-quarter net income of $14 million, or 13 cents a share, topping the mean estimate of analysts polled by Thomson Financial of 11 cents a share.
Revenue for the three months ended Dec. 31 rose 35% to $183.7 million from $135.6 million in the same period a year earlier. Wall Street's consensus was for revenue of $154.5 million.
UBS (NYSE:UBS) reiterated its buy rating and $15 price target on the stock, saying it expects the shares to be up 'substantially' on the fourth-quarter results and once Wall Street fully digests the implication of the BioSpin deal that closed on Feb. 26.
Bruker Corp. acquired Bruker BioSpin Group for $388 million in cash and 57.5 million in Bruker Corp. shares, valued at $526 million. The total value of the transaction is about $914 million.
http://money.cnn.com/news/newsfeeds/articles/newstex/AFX-0013-23363509.htm
WOW...big news here....
Thu 7:13am BRKR InPlay: Bruker BioSciences beats by $0.06, beats on revs - Briefing.com
ONLY TWO BOARDMARKS....THAT IS A SAD STATE OF AFFAIRS....NUMBER ONE UNDER-RATED COMPANY ON INVESTORSHUB,(sorry for caps, sometimes they are needed)
Bruker Corporation Reports Record Revenues and Earnings for the Fourth Quarter and Full Year 2007
(WE GOT A LIVE ONE HERE...jt says)
Thursday February 28, 7:00 am ET
Full Year 2007 Revenue Increased 19% (after Currency Adjustments) to $547.6 Million, and Full Year 2007 Net Income Grew 70% to $31.5 Million
BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (NASDAQ: BRKR - News) today reported financial results for the fourth quarter and full year ended December 31, 2007. The financial information included herein does not include the results of the Bruker BioSpin Group, which was acquired on February 26, 2008, but only the financial results of the standalone Bruker BioSciences Corporation, as it legally existed on December 31, 2007.
ADVERTISEMENT
On February 26, 2008, Bruker BioSciences Corporation closed its acquisition of the Bruker BioSpin Group, and renamed itself Bruker Corporation. Under US GAAP, this transaction will be accounted for as an acquisition of businesses under common control, and as a result all one-time transaction costs are expensed in the period in which they are incurred, rather than being added to goodwill. In addition, after the closing of the transaction all historical consolidated balance sheets, statements of operations, statements of cash flows and notes to the consolidated financial statements in future filings with the Securities and Exchange Commission will be restated by combining the historical consolidated financial statements of Bruker BioSciences Corporation with those of the Bruker BioSpin Group. The Bruker BioSpin Group standalone financial results, as well as combined financial results for Bruker Corporation, are expected to be released in mid-March 2008. At that time, the newly combined Company will also provide an update on its financial goals for the year 2008.
Financial Results of Bruker BioSciences (excluding the Bruker BioSpin Group)
For the fourth quarter of 2007, revenue increased by 35% to $183.7 million, compared to revenue of $135.6 million in the fourth quarter of 2006. Excluding the effects of foreign currency translation, fourth quarter 2007 revenue increased organically by 26% year-over-year.
Net income in the fourth quarter of 2007 increased 44% to $14.0 million, or $0.13 per diluted share, compared to net income of $9.7 million, or $0.09 per diluted share, in the fourth quarter of 2006. Included in GAAP net income for the fourth quarter of 2007 were after-tax charges of $4.3 million, or $0.04 per diluted share, for expenses related to the acquisition of the Bruker BioSpin Group.
For the full year 2007, revenue increased by 26% to $547.6 million, compared to revenue of $435.8 million for the full year 2006. Excluding the effects of foreign currency translation, full year 2007 revenue increased by 19% year-over-year, including 17% organic growth and 2% growth from acquisitions.
Net income for the full year 2007 increased 70% to $31.5 million, or $0.30 per diluted share, compared to net income of $18.5 million, or $0.18 per diluted share, during the full year 2006. Included in GAAP net income for the full year 2007 were after-tax charges of $4.7 million, or $0.04 per diluted share, for expenses related to the acquisition of the Bruker BioSpin Group. For comparison, included in GAAP net income for the year 2006 were after-tax charges of $5.0 million, or $0.05 per diluted share, for expenses related to the acquisition of Bruker Optics.
During the fourth quarter of 2007, cash flow from operations was $36.4 million and free cash flow, defined as operating cash flow less capital expenditures, was $34.3 million. During the full year 2007, cash flow from operations was $26.3 million and free cash flow was $10.8 million. As of December 31, 2007, the Company had $72.9 million in cash and cash equivalents, and $38.1 million in outstanding debt.
Commenting on the Company’s financial performance, Frank Laukien, President and CEO, said: “We had an outstanding fourth quarter, and we are very pleased that during 2007 we have achieved excellent top-line growth, with all three operating divisions delivering currency-adjusted double digit growth year-over-year. Even more importantly, our rapid growth, our continued operating margin expansion and our decreasing effective tax rate contributed to significantly improved bottom-line performance year-over-year, as well as to solid operating and free cash flow.”
He continued: “Bruker BioSciences has made very good progress over the last three years. We will continue to strive for fast growth and further margin improvements in order to reach industry-standard profitability, and we will put a significant focus on balance sheet management and cash flow generation. We are optimistic that the renamed Bruker Corporation, which as of two days ago includes the Bruker BioSpin Group, is well positioned to serve our customers and markets with high-performance products and solutions. Despite the uncertainty in the macro-economic outlook, at this point the Company expects significant further financial improvements in the year 2008.”
EARNINGS CONFERENCE CALL
Bruker Corporation will host an operator-assisted earnings conference call at 9 a.m. Eastern Time on Thursday, February 28, 2008. To listen to the webcast, investors can go to www.bruker-biosciences.com and click on the live web broadcast symbol. The webcast will be available through the Company web site for 30 days. Investors can also listen and participate on the telephone in the US and Canada by calling 888-339-2688, or 617-847-3007 outside the US and Canada. Investors should refer to the Bruker Corporation Quarterly Earnings Call. A telephone replay of the conference call will be available one hour after the conference call by dialing 888-286-8010 in the US and Canada, or 617-801-6888 outside the US and Canada, and then entering replay pass code 11927586.
ABOUT BRUKER CORPORATION
As of February 26, 2008, the renamed Bruker Corporation (NASDAQ: BRKR - News) has become the parent company of the entire Bruker group of companies. After the closing of the acquisition of the Bruker BioSpin Group, Bruker Corporation now operates in two segments, the life science and analytical (LSA) systems segment, and the international advanced superconductor (IAS) segment. For more information, please visit www.bruker-biosciences.com
CAUTIONARY STATEMENT
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, intellectual property rights, litigation, and exposure to foreign currency fluctuations. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2006, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements other than as required by law.
Bruker Corporation (excluding the Bruker BioSpin Group)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
Three Months Ended December 31,
Twelve Months Ended December 31,
2007 2006 2007 2006
Product revenue $ 164,910 $ 120,444 $ 482,153 $ 384,548
Service revenue 18,384 14,960 64,553 49,930
Other revenue 449 221 870 1,356
Total revenue 183,743 135,625 547,576 435,834
Cost of product revenue 85,605 63,214 252,130 206,628
Cost of service revenue 12,492 9,239 42,308 29,872
Total cost of revenue 98,097 72,453 294,438 236,500
Gross profit margin 85,646 63,172 253,138 199,334
Operating Expenses:
Sales and marketing 31,074 25,212 105,983 84,007
General and administrative 10,392 8,663 34,058 28,982
Research and development 16,164 13,464 58,466 49,959
Acquisition related charges 4,294 (105 ) 4,664 5,724
Total operating expenses 61,924 47,234 203,171 168,672
Operating income 23,722 15,938 49,967 30,662
Interest and other income (expense), net (530 ) 236 (1,355 ) 3,758
Income before income tax provision and minority interest in consolidated subsidiaries
23,192 16,174 48,612 34,420
Income tax provision 9,129 6,533 16,784 15,931
Income before minority interest in consolidated subsidiaries
14,063 9,641 31,828 18,489
Minority interest in consolidated subsidiaries 44 (67 ) 299 8
Net income $ 14,019 $ 9,708 $ 31,529 $ 18,481
Net income per share:
Basic $ 0.13 $ 0.10 $ 0.30 $ 0.18
Diluted $ 0.13 $ 0.09 $ 0.30 $ 0.18
Weighted average shares outstanding:
Basic 104,508 101,501 103,702 101,512
Diluted 107,180 103,370 106,769 102,561
Bruker Corporation (excluding the Bruker BioSpin Group)
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
December 31, December 31,
2007 2006
ASSETS
Current assets:
Cash and short-term investments $ 72,876 $ 52,147
Accounts receivable, net 114,938 79,604
Due from affiliated companies 7,203 9,028
Inventories 171,332 134,504
Other current assets 29,281 19,461
Total current assets 395,630 294,744
Property and equipment, net 103,100 90,349
Intangible and other assets 54,483 48,094
Total assets $ 553,213 $ 433,187
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Short-term borrowings $ 31,716 $ 21,857
Accounts payable 32,584 23,102
Due to affiliated companies 8,326 5,901
Other current liabilities 180,327 144,268
Total current liabilities 252,953 195,128
Long-term debt 6,394 22,863
Other long-term liabilities 34,702 23,491
Minority interest in subsidiaries 505 239
Total shareholders' equity 258,659 191,466
Total liabilities and shareholders' equity $ 553,213 $ 433,187
Contact:
Bruker Corp.
Michael Willett, +1 978-663-3660, ext. 1411
Investor Relations Officer
ir@bruker-biosciences.com
--------------------------------------------------------------------------------
Source: Bruker Corp.
Form 8-K for BRUKER BIOSCIENCES CORP
--------------------------------------------------------------------------------
27-Feb-2008
Entry into a Material Definitive Agreement, Termination of a Material Def
Item 1.01. Entry into a Material Definitive Agreement
On February 26, 2008, Bruker Corporation, formerly known as Bruker BioSciences Corporation (the "Company"), entered into a senior secured $380 million Credit Agreement by and among the Company and certain of its foreign subsidiaries as borrowers, Citibank, N.A. as syndication agent, RBS Citizens, National Association, Deutsche Bank AG and Dresdner Bank AG as co-documentation agents, JPMorgan Chase Bank, N.A., as administrative agent for itself and the other lenders party thereto, and the several banks or other financial institutions or entities from time to time party thereto as lenders (the "Credit Agreement"). The Credit Agreement provides for a five-year revolving credit facility in the U.S. Dollar equivalent amount of up to $230.0 million, comprised of sub-facilities for revolving loans, swing-line loans, letters of credit and foreign borrowings, plus a five-year term loan facility in the amount of $150.0 million. The Credit Agreement also provides for an uncommitted incremental facility whereby, under certain circumstances, the Company may be able to increase the amount borrowed under the revolving credit facility or incur additional term loans in an aggregate amount not to exceed $100.0 million.
The Company entered into the Credit Agreement to finance a portion of the consideration paid in connection with the acquisition of the companies of the Bruker BioSpin Group, which was completed on February 26, 2008. Remaining availability under the Credit Agreement may be used by the Company and its subsidiaries for working capital and other general corporate purposes, including permitted acquisitions.
Amounts outstanding under the credit facilities and term loan facility bear interest at a rate equal to, at the Company's option, the British Bankers Association LIBOR rate plus a margin rate ranging from 0.40% to 1.05% with respect to loans under the revolving credit facility and from 0.50% to 1.25% with respect to loans under the term loan facility, based on the Company's leverage ratio, or the higher of the Federal Funds Rate plus 0.50% and the prime rate announced by JPMorgan Chase Bank. The Company has also agreed to pay a quarterly facility fee ranging from 0.10% to 0.20% per annum of the aggregate amount available under the revolving credit facility.
The revolving credit and term loan facilities are secured by liens on all of the stock of the Company's domestic subsidiaries and 65% of the stock of the Company's direct or indirect material foreign subsidiaries. In addition, the Company and each of its direct and indirect material subsidiaries unconditionally guarantee the obligations of the borrowers under the Credit Agreement.
The obligations of the Company and any additional subsidiary borrowers under the Credit Agreement may be accelerated upon the occurrence of an event of default under the Credit Agreement. The Credit Agreement specifies customary events of default including, without limitation, payment defaults, defaults in the performance of affirmative and negative covenants, the inaccuracy of representations and warranties, bankruptcy and insolvency related events, certain ERISA events, material judgments, and a change of control default.
The Credit Agreement also contains affirmative, negative and financial covenants customary for financings of this type. The negative covenants include, among others, restrictions on liens, indebtedness of the Company and its subsidiaries, asset sales, dividends, and transactions with affiliates. The financial covenants include total leverage and minimum interest coverage ratios of the Company.
The foregoing description of the Credit Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Credit Agreement, which is attached hereto as Exhibit 10.1. From time to time in the ordinary course of business, certain of the lenders and their affiliates have provided, and may in the future provide, customary commercial and investment banking services to the Company.
. . .
Item 1.02. Termination of a Material Definitive Agreement.
In connection with obtaining the new credit facilities discussed under Item 1.01, on February 21, 2008 the Company terminated the Demand Promissory Note dated as of July 5, 2006, as amended, from the Company to RBS Citizens, N.A. (formerly known as Citizens Bank of Massachusetts).
Item 2.01. Completion of Acquisition or Disposition of Assets.
On February 26, 2008, Bruker Corporation, formerly known as Bruker BioSciences Corporation (the "Company"), completed the previously announced acquisition of all of the outstanding equity of the companies comprising the Bruker BioSpin Group from the Bruker BioSpin Group shareholders in accordance with the terms of the following agreements: 1) the stock purchase agreement, dated as of December 2, 2007, by and among the Company, Bruker BioSpin Inc. and the stockholders of Bruker BioSpin Inc. (the "U.S. Stock Purchase Agreement"); 2) the share purchase agreement, dated as of December 2, 2007, by and among the Company, certain of the Company's wholly-owned German subsidiaries, Bruker Physik AG, Techneon AG and the shareholders of Bruker Physik (the "German Share Purchase Agreement"); and 3) the agreement and plan of merger, dated as of December 2, 2007, by and among the Company, Bruker BioSpin Beteiligungs AG, Bruker BioSpin Invest AG and the shareholders of Bruker BioSpin Invest AG (the "Swiss Merger Agreement"). As previously reported, at the Company's special meeting of stockholders, held on February 25, 2008, the Company's stockholders approved the acquisitions and the issuance of shares of the Company's common stock in connection with the acquisitions. Upon completion of the acquisitions, the Company amended its certificate of incorporation and, effective as of February 26, 2008, was renamed Bruker Corporation.
Prior to the completion of the acquisition of the Bruker BioSpin Group, the Company's chief executive officer and chairman of the board, Frank H. Laukien, and certain of his family members owned stock in both the Company and the companies of the Bruker BioSpin Group. Dr. Laukien and his related family members owned an aggregate of 52% of the Company's common stock and 100% of the shares of the Bruker BioSpin Group companies being acquired. Following the completion of the acquisition, Dr. Laukien and his related family members own, in the aggregate, approximately 69% of the outstanding shares of common stock of the Company. In addition, Dr. Laukien's half brother, Dirk D. Laukien, senior vice president of the Company, was elected to serve as a Class II director for a term expiring at the Company's 2008 annual meeting of stockholders.
At the closing, the Company paid an aggregate of $914 million of consideration to the Bruker BioSpin Group stockholders, of which approximately $388 million was paid in cash and approximately $526 million was paid in restricted unregistered shares of Company common stock, based on the trailing ten trading day average closing price of its common stock ending two days prior to the signing of the transaction agreements of $9.14 per share. Pursuant to the transaction agreements, the Company issued an agreed-upon number of 57,544,872 shares of unregistered stock, with a market value as of February 25, 2008 of approximately $[ ], to the Bruker BioSpin Group shareholders. As a result of the transaction, the companies of the Bruker BioSpin Group became wholly-owned subsidiaries of the Company.
$92.0 million of the cash payment to the Bruker BioSpin Group shareholders will be held in escrow until the later of (x) the thirtieth day following receipt by the Company of the Bruker BioSpin Group's combined audited financial statements for the fiscal year ended December 31, 2007, or (y) the resolution of any indemnification claim pending as of the receipt of such audited financial statements. In addition, $6.75 million of the cash payment to the Bruker BioSpin Group shareholders will be held in a working capital escrow until the later of (x) the twentieth day after the Company delivers a closing balance sheet to the Bruker BioSpin Group shareholders, which balance sheet is to be delivered within 90 days of the closing of the acquisition, or (y) the resolution of any objections to the balance sheet.
The U.S. Stock Purchase Agreement, the German Share Purchase Agreement and the Swiss Merger Agreement, filed as Exhibit 2.1, 2.2, and 2.3, respectively, to the Company's Current Report on Form 8-K, dated December 2, 2007 and filed with the Securities and Exchange Commission on December 3, 2007, is incorporated herein by reference. The foregoing descriptions of the U.S. Stock Purchase Agreement, the German Share Purchase Agreement, and the Swiss Merger Agreement are qualified in their entirety by reference to the full text of the agreements. A copy of the press release issued by the Company on February 26, 2008 regarding the completion of the acquisitions is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
--------------------------------------------------------------------------------
Item 2.03. Creation of a Direct Financial Obligation or an
Obligation under an Off-Balance Sheet Arrangement of a Registrant.
The information set forth in Item 1.01 with respect to the Credit Agreement is incorporated herein in its entirety.
Item 3.02. Unregistered Sales of Equity Securities
Pursuant to the Swiss Merger Agreement described above in Item 2.01 of this current report, which disclosure is incorporated herein by reference, the Company issued restricted unregistered shares of the Company's common stock to the Bruker BioSpin Group shareholders as consideration for their shares of Bruker BioSpin Invest AG. The issuance of these securities was in reliance on the exemption from registration provided by Section 4(2) of the Securities Act of 1933. Based upon the small number of holders of Bruker BioSpin Invest AG capital stock receiving restricted shares of the Company's common stock, their financial position and sophistication, and the absence of any general solicitation, the transaction was determined not to involve any public offering.
Item 5.02. Departures of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers
In connection with the closing of the acquisitions, Dr. Dirk Laukien and Tony Keller were elected to the Company's Board of Directors for terms expiring at the Company's annual meeting in 2008 and 2009, respectively.
Item 9.01. Financial Statements and Exhibits.
(a) Financial Statements of Businesses Acquired
The required financial statements relating to the acquisition of the Bruker BioSpin Group are not included in this Current Report. The Company will file the required financial statements by amendment no later than 71 calendar days after the date this Current Report on Form 8-K is required to be filed with the Securities and Exchange Commission.
(b) Unaudited Pro Forma Financial Information
The required pro forma financial information is not included in this Current Report. The Company will file the required pro forma financial information by amendment no later than 71 calendar days after the date this Current Report on Form 8-K is required to be filed with the Securities and Exchange Commission.
(d) Exhibits
Number
10.1 Credit Agreement dated as of February 26, 2008 among the Company, Bruker
AXS GmbH, Bruker Daltonik GmbH, Bruker Optik GmbH, Bruker Physik GmbH,
Bruker BioSpin Invest AG, Bruker BioSpin AG and Bruker BioSpin
International AG, the other foreign subsidiary borrowers from time to time
party thereto, the lenders from time to time party thereto, Citibank, N.A.
as Syndication Agent, and RBS Citizens, National Association, Deutsche Bank
AG and Dresdner Bank AG as Co-Documentation Agents, and JPMorgan Chase
Bank, N.A., as Administrative Agent.
99.1 Press release dated February 26, 2008.
February 26, 2008 - 5:15 PM EST Announces Closing
Bruker Corporation Announces Closing of the Acquisition of the Bruker BioSpin Group
The former Bruker BioSciences Corporation, presently being renamed Bruker Corporation (NASDAQ: BRKR), announces that today it has closed the previously-announced acquisition of the Bruker BioSpin Group. Approximately 57.5 million new unregistered shares of BRKR common stock were issued for the stock component of the acquisition consideration. At the closing price per share of $10.86 on February 25, 2008, the stock portion of the aggregate consideration for the acquisition was approximately $624.9 million.
ABOUT BRUKER (NASDAQ: BRKR)
As of February 26, 2008, the renamed Bruker Corporation has become the parent company of the entire Bruker group of companies. After the closing of the acquisition of the Bruker BioSpin Group, Bruker Corporation now operates in two segments, the life science and analytical (LSA) systems segment, and the international advanced superconductor (IAS) segment. For more information, please visit www.bruker-biosciences.com.
CAUTIONARY STATEMENT OF BRUKER CORPORATION
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, intellectual property rights, litigation, and exposure to foreign currency fluctuations. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2006, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements other than as required by law.
Bruker Corp.
Michael Willett, +1 978-663-3660, ext. 1411
Investor Relations Officer
ir@bruker-biosciences.com
Source: Business Wire (February 26, 2008 - 5:15 PM EST)
News by QuoteMedia
www.quotemedia.com
An interesting article about Bruker:
Enjoy Friend,
JT
http://buswire.ocr.wisc.edu/leadstory/200709.php
(from last Sept)
Interesting:
http://www.digitallook.com/cgi-bin/dlmedia/security.cgi?username=&ac=&csi=131185
(Stong buy reco?)
MACD and CMF now reversing
ADX is also looking good...
Cheers Shareholders,
JT
Almost 100% since post in reply..."nice price to buy"
MSC still like this company?
(notice I'm not mod anymore)(thanks to ADMIN)(they want mods on boards but then remove you off for not posting?) weak...
anyway....
I still like Bruker and should see some nice new 52 week highs possibly.
Thanks and ttys Friend,
JT
Bruker BioSciences approves merger, name change
Monday February 25, 11:36 am ET
Bruker BioSciences Corp. said Monday the company's shareholders have approved the acquisition of the companies comprising the Bruker BioSpin Group.
Billerica, Mass.-based Bruker BioSciences (Nasdaq: BRKR - News) said stockholders also approved changing the name of the company to 'Bruker Corp.'
The acquisition of Bruker BioSpin Group is expected to close this month, according to a release form the company.
Published February 25, 2008 by the Boston Business Journal
Bruker AXS Announces MICROSTAR ULTRA II High Brightness X-ray Source with Novel ULTRA FOCUSTM Electron Optics
November 15, 2007
MADISON, Wis.--(BUSINESS WIRE)--Bruker AXS Inc., a leading global developer and provider of life science, materials research and industrial X-ray analysis tools, today announced its new MICROSTAR ULTRA II, the newest version of the 2007 R&D Award winning MICROSTAR ULTRA ultra-bright X-ray source for structural biology.
Its innovative new ULTRA FOCUSTM electron optics (patent pending) give an enhancement in intensity equivalent to a doubling of the anode rotation frequency and thus produce an extremely high intensity X-ray beam, more than 30 times brighter than a conventional rotating-anode generator. The intensity of the MICROSTAR ULTRA II now surpasses many second-generation synchrotron beam lines. The introduction of the MICROSTAR ULTRA II will change the way protein crystallography is done as most routine de novo structures can now be routinely determined in the home laboratory with time consuming trips to the synchrotron reserved for high resolution data collections, only.
“Our mission is to provide increasingly brighter sources, but always with the exemplary reliability and low cost of ownership that our users have come to expect from the MICROSTAR family”, said Dr. Roger Durst, Chief Technology Officer for Bruker AXS, ”With the development of the novel ULTRA FOCUSTM, we are fulfilling this promise.”
The Bruker AXS ultra-bright MICROSTAR ULTRA II™ X-ray source for structural biology allows the collection of quality data that were previously difficult or impossible to analyze in the home laboratory.
ABOUT BRUKER AXS
Bruker AXS is a leading developer and provider of life science, materials research and industrial X-ray analysis and spark-OES tools. For more information, please visit www.bruker-axs.com
Proxeon and Bruker Daltonik Announce OEM Agreement
November 15, 2007 12:05 AM Eastern Time
Bruker Daltonik to Offer Proxeon’s EASY-nLC, a Nanoscale Chromatography System, as Part of their LC/MS Product Portfolio
ODENSE, Denmark & BREMEN, Germany--(BUSINESS WIRE)--Proxeon A/S and Bruker Daltonik GmBH today announced that the companies have entered into an OEM agreement. Under the agreement, Bruker Daltonik will sell Proxeon’s nanoscale chromatography system, EASY-nLC™, together with their well-established range of products for mass spectrometry, beginning initially in the Europe region.
“Combining our range of proteomics MS products with the novel nanoLC system from Proxeon takes proteomics analysis to a new level in terms of performance, reliability and ease-of-use, answering the increasing demand for integrated solutions,” said Dr. Alexander Harder; Director of Product Management of Bruker Daltonik.
EASY-nLC is a fully integrated, split-free nanoscale LC system, optimized for use with mass spectrometry and in particular LC-MS applications in proteomics. The product is already in use in prestigious proteomics laboratories and will also continue to be sold through the Proxeon sales team. Bruker Daltonics offers a well-established range of mass spectrometry systems and solutions that are widely used in proteomics research, including their HCTultra™ ion trap, micrOTOF-Q™, and apex ultra™ instrument series. The Easy-nLC and MS systems are already completely integrated via Bruker Compass™ software, offering significant convenience and productivity advantages for proteomics researchers. The combined system will be sold by Bruker Daltonik through their sales and marketing organization.
“Bruker Daltonics is one of the world leading MS proteomics companies. This OEM agreement is an excellent opportunity to reach out and offer our outstanding product to a larger group of researchers,” explained Mårten Winge, CEO of Proxeon.
No financial terms of the agreement are disclosed.
http://tinyurl.com/326nbc
Bruker BioSpin Launches Analytical Services Program
[November 1, 2007 Bruker BioSpin]
Billerica, Massachusetts, November 1, 2007
Bruker BioSpin is pleased to announce the launch of its Bruker Analytical Services program, offering for-fee analytical measurements. The wide range of techniques currently includes NMR, FTIR and Raman spectroscopy, while expansions into additional techniques are planned. Our state of the art laboratories provide customers with direct access to the latest Bruker technologies, operated by our knowledgeable applications experts to assure the highest quality service with a quick turn around. The Bruker Analytical Services program will enable customers to lower infrastructure costs at their laboratory site, while still obtaining high quality information for their research applications.
"Early service opportunities highlight our strengths in NMR, TD-NMR, and FTIR applications," said Paul Dawson, Sales Manager for the Bruker Analytical Services Division. "With demand coming from such widespread markets as Pharmaceutical, Biotech, Petroleum industry and Academia, we are expanding our capabilities every day with resources from the entire Bruker family of technologies."
By opening the door to the vast resources of both the technology and the people that make Bruker a leader in the instrumentation industry, Bruker Analytical Services provides a powerful asset of innovation, excellence, and quality to a wide variety of project needs.
About Bruker BioSpin
The global Bruker BioSpin group designs, manufactures and distributes enabling life science and analytical research tools based on magnetic resonance core technology. The Company?s technology platforms include NMR, EPR, MRI, as well as superconducting magnets and superconducting wire. Bruker BioSpin's NMR division is the worldwide technology and market leader in NMR. For more information, please visit www.bruker-biospin.com.
http://www.spectroscopynow.com/coi/cda/detail.cda?id=17485&type=News&chId=2&page=1
Bruker mentioned in the following report
5 Low-Priced, High-Star Stocks
By Brian D. Pacampara October 9, 2007 - The Motley Fool
Buying stocks simply because they trade for less than $10 remains one of the "lowest" -- but most tempting -- forms of investing out there.
After all, nothing trounces Mr. Market quite like a $2 stock that moves into double digits over just a short period of time. Unfortunately, thanks to the numerous risks that low-priced stocks carry, these mega-multibagger returns don't occur as frequently as one would hope.
Price means nothing
Here at the Fool, we do our darnedest to diagnose and prevent the critical stock affliction known as "cheap-osis" -- the belief that a stock's per-share price, on its own, tells you whether a stock is cheap or expensive, attractive or unattractive, a winner or a loser.
Through the use of splits and reverse splits, management can make the price of its shares literally anything they want. That's the reason a $100 stock like Alcan (NYSE: AL) might very well be a great opportunity, while most penny stocks are too wild to buy at any price.
Your weekly dose of sweet 'n' low
Sadly, though, some incidents of cheap-osis will never be cured completely. So, with the help of our Motley Fool CAPS intelligence database, we'll screen for stocks trading at less than $10 that also have enough investment merit to earn a CAPS rating of five stars.
Without further ado:
Company Price Market Cap(in millions) Industry
iGATE (Nasdaq: IGTE)$9.43 $502 Information Technology Services
Bruker BioSciences (Nasdaq: BRKR)$8.84 $931 Scientific instruments
SeaChange International $7.47 $220 Processing systems
NexCen Brands (Nasdaq: NEXC) $6.95 $354 Diversified investments
Northern Orion Resources (AMEX: NTO)$6.39 $984 Metals and minerals
As always, don't view these stocks as formal recommendations, but rather as ideas you may want to research further.
Opening the iGATEs
A great thing about CAPS is being able to easily find stocks that capitalize on strong, large-scale trends. iGATE, for example, is one of our community's favored ways to play the rampant growth of offshore outsourcing services. With the stock recently receiving a five-star rating, it might be worth a timely look, too.
Historically, iGATE's operating margins have been less than stellar, but over the last couple of years, they've certainly improved -- a positive sign, to be sure. Strong alliances with the likes of Microsoft (Nasdaq: MSFT) and IBM (NYSE: IBM) don't exactly hurt the bullish case, either. Throw in the fact that co-founders Ashok Trivedi and Sunil Wadhwani continue to own nearly 60% of the company, and you've got a low-priced stock with some top-notch characteristics.
CAPS player capsgolmal adds:
The company has been in business for 20 + years and made big missteps in Internet bubble market, but is now back on track. It should grow revenue and margins from here-on. It doesn't need to do anything special for the outsourcing tide to carry it very far.
Rule Bruker
Bruker BioSciences, a Massachusetts-based provider of X-ray technology, is another low rider for which our community has high hopes. Like iGATE, Bruker just recently regained its five-star status, so it might make sense to give it a quick scan -- especially if it's growth you're trying to detect.
In its latest quarter, Bruker posted earnings growth of 100%, while analysts expect profits to grow 28% annually for the next five years. The company derives half of its sales from overseas -- primarily Germany -- so it might also offer investors a way to benefit from the weak U.S. dollar. With a PEG of 1.25, BRKR isn't exactly cheap, but those growth rates should at least warrant a place on your watch list.
spildale comments on the opportunity:
This company is expanding by making acquisitions of complimentary businesses. Also, because it is in the medical imaging field, Bruker will continue to grow and expand with excellent cash flow.
The Foolish conclusion
Despite our Foolish attempts to educate the investment public about cheap-osis, the allure of low-priced stocks is simply undeniable. The good news, though, is that there are indeed single-digit wonders out there that can also make great investments.
http://tinyurl.com/2n936m
Out of the Gate: Bruker Jumps
Bruker BioSciences Rises After Bear Stearns Upgrades Stock, Predicts Earnings Growth Into 2009
October 05, 2007: 10:31 AM EST
NEW YORK (Associated Press) - Shares of Bruker BioSciences Corp., which makes X-ray technology and molecular analysis tools, climbed Friday after a Bear Stearns analyst upgraded the stock, saying the company's profit should grow 30 percent in both 2008 and 2009.
Stephen Unger raised his rating to "Outperform," or "Buy," from "Peer Perform," and said the stock should rise to $12 by the end of 2008. He expects the company to report an adjusted profit of 23 cents per share this year, matching last year's results.
Unger forecast profit of 30 cents per share in 2008 and 39 cents per share in 2009. He said Bruker's revenue should grow more than 10 percent per year over that time, and its profit margins will increase.
The stock picked up 53 cents, or 6.2 percent, to $9.13. Unger's price target implies 39.5 percent growth from Bruker's Thursday closing price of $8.60.
The weak U.S. dollar is good news for Bruker, Unger said in a client note, as about 75 percent of its revenue _ and all of its operating profit _ comes from overseas. Almost half of its total profit comes from Germany, he added, and starting in 2008, Bruker will be able to pay lower taxes in the country.
Analysts polled by Thomson Financial expect Bruker to earn 33 cents per share in 2008 and 43 cents per share the next year.
Three analysts now rate the Billerica, Mass., company at "Buy," and one assigns a "Neutral" rating.
http://tinyurl.com/2j49fg
Bruker mentioned in this article (see bold section)
Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development
September 20, 2007: 07:00 AM EST - CNN Money
CARLSBAD, Calif., Sept. 20 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announced today that its wholly owned subsidiary, Ibis Biosciences, Inc. (Ibis), has been awarded four new government contracts totaling up to $4.2 million to advance the detection and identification of microbial threat agents for biodefense applications. Three of these contracts are from the Department of Homeland Security Science and Technology Directorate (DHS-S&T) and total up to approximately $3.3 million and a fourth contract, worth up to $0.9 million, is from the Defense Threat Reduction Agency (DTRA), an agency within the Department of Defense. These contracts will fund Ibis' planned development of advanced sample preparation methodologies and validation of applications on the Ibis T5000(TM) for broad biological weapon detection, the advancement of Ibis' microbial forensics applications, and the enhancement of Ibis' microbial database.
"We are pleased with the ongoing government support and the opportunity to continue to advance our technology and applications in the biodefense arena," said Michael Treble, President of Ibis and Vice President of Isis. "These contracts support the Ibis business model to commercialize the Ibis T5000 in multiple business sectors, including government biodefense and infectious disease surveillance, healthcare-associated infection control, infectious disease research and, in the future, in vitro diagnostics."
As part of the contracts awarded by DHS-S&T, Ibis will continue to develop broad biological applications to identify and characterize important bacterial and viral agents that are considered crucial to maintain homeland security. Ibis will also use the funding to advance the application of the Ibis T5000 system in microbial forensics, a type of forensics used in the investigation of crimes involving infectious organisms. Under the DTRA contract, Ibis will broaden its core technology in the area of biodefense through advances in sample preparation to allow detection of trace amounts of broad groups of microbial agents.
ABOUT THE IBIS T5000 BIOSENSOR SYSTEM AND IBIS BIOSCIENCES, INC.
Ibis Biosciences, Inc., a wholly owned subsidiary of Isis Pharmaceuticals, has developed the Ibis T5000 Biosensor System for rapid identification and characterization of infectious agents. The Ibis T5000 is capable of identifying virtually all bacteria, viruses and fungi, and can provide information about drug resistance, virulence and strain type of these pathogens. Commercial applications for the Ibis T5000 Biosensor System include epidemiologic surveillance, monitoring of pandemic diseases, identification of emerging or previously unknown pathogens, forensic characterization of human samples, identification of sources of hospital-associated infections, and, in the future, human infectious disease diagnostics. Bruker Daltonics, a subsidiary of Bruker BioSciences Corporation, is globally responsible for manufacture, order processing, installation and service of Ibis T5000 instruments. Ibis Biosciences develops, manufactures and markets Ibis T5000 assay kits. Additional information about Ibis Biosciences can be found by selecting the Ibis Biosciences link from Isis' homepage at http://www.isispharm.com.
Ibis Biosciences has received development funding from U.S. government agencies including the Defense Advanced Research Projects Agency (DARPA), the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), the Federal Bureau of Investigation (FBI), the Department of Homeland Security (DHS), and others.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing drugs for a wide variety of diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.
This press release includes forward-looking statements regarding the development and commercialization of the Ibis T5000 Biosensor System, Ibis' technology, and the revenue potential of certain government contracts. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals or projections. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, in developing and commercializing systems to identify infectious organisms that are effective and commercially attractive, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2006, and its quarterly report on Form 10-Q for the quarter ended June 30, 2007, which are on file with the SEC. Copies of this and other documents are available from the Company.
In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.
Isis Pharmaceuticals, Ibis Biosciences and Ibis T5000 are registered trademarks or trademarks of Isis Pharmaceuticals, Inc.
http://money.cnn.com/news/newsfeeds/articles/prnewswire/LATH01020092007-1.htm
Instrument makers harness technology to pursue budding applications for their tools
August 13, 2007 Volume 85, Number 33 pp. 26-31
Marc S. Reisch - Chemical & Engineering News
SCIENTIFIC INSTRUMENT MAKERS are on a mission to take their instruments out of the lab and put them into everyone's hands. They want to make their mass spectrometers, infrared spectrophotometers, and ion detectors ubiquitous. In a world that fears terrorists, contaminated food, and airborne pollutants, instrument companies are working to design simple-to-operate, portable, affordable devices to identify threats or ensure safety.
"If God made it, we can test for it," says Richard F. Begley, president of analytical sciences at PerkinElmer. "A day will come when people will want to know the details of what is in the water they drink, the air they breathe, and the food they eat."
Ten years from now, Begley predicts, people will notice more instruments in use out of the lab and in the field. Further into the future, "everybody will be able to buy a 'Star Trek' tricorder," he says, referring to the scanning tool used to analyze unfamiliar environments in the science-fiction television series. Many people already have glucose- and heart-monitoring equipment in their homes, Begley points out.
A maker of some of the most sophisticated scientific instruments, PerkinElmer designs and sells items such as high-throughput flash luminescent analyzers that are used by pharmaceutical laboratories to screen for potential new drugs. And although Begley might seem the wide-eyed dreamer when he suggests that complex, sophisticated devices can be "dumbed down," other executives at scientific instrument firms see eye to eye with him.
In fact, for some instrument makers, the future is already here. Cynthia Cai, petrochemical and chemical industry manager at instrument maker Agilent, says her firm strives to design simple, rugged, and portable instruments. Recent terrorism concerns, along with technical advances, have prompted the design of portable equipment rugged enough to be parachuted into war zones for chemical weapons testing, she points out.
Another company, Bruker Daltonics NBC Detection, also has chemical weapons on its corporate mind. Civil emergency response teams are getting the firm's handheld ion detection units, which will allow them to quickly determine if any suspected chemical warfare agents are present at the site of a terrorist attack, says Frank Thibodeau, vice president of Bruker.
.............. continued at link
http://pubs.acs.org/cen/business/85/8533bus1.html
TeraView and Bruker gain Terahertz sales in Asia
Edited by the Laboratorytalk Editorial Team on 9 August 2007
TeraView has received orders and installed systems for key Terahertz customers in Japan, Korea and China
In each sale, TeraView has worked closely with its partner in the analytical industry, Bruker Optics, to ensure that customers received the right product with a high level of commitment to after-sales support. Each is a world first - TeraView has provided the first commercial Terahertz products in each of these territories.
In some instances, the company secured contracts ahead of domestic competition.
Customers include Takeda, the largest Japanese pharmaceutical company working on drug development, a medical imaging laboratory at the Chinese University of Hong Kong looking at early stage cancer detection, and other customers in China and Korea which will also act as reference sites for future business.
According to Don Arnone, chief executive officer of TeraView: 'The creation of our Asian business is the result of a considerable amount of hard work over the past couple years.
'The fact that we have beaten out domestic competitors is testament to the high performance of our products and our heavy investment in customer support, both of which are unparalleled in this industry.
'The success of our Asian business is evidence of our commitment to provide these customers with total solutions to their business needs, which is of up-most importance to users in this region '.
In addition, Arnone noted that: 'the relationship with Bruker Optics was also fundamental to our success in Asia, and is another example of how our business model of working with partners to address the broader analytical market has built value for TeraView, Bruker, and most importantly for our customers'.
TeraView's chief scientific officer, Professor Sir Michael Pepper, FRS, said: 'We are in an ideal position to support these customers because of the company's substantial expertise and personnel dedicated to the science behind these applications.
'TeraView has pioneered developments where initially nobody suspected that Terahertz could be of importance '.
Michael Verst, president of Bruker Optics Japan and Korea: 'Bruker Optics is growing rapidly in the Asian markets, by providing high-end research, analytical and process analysis instruments to a variety of customers.
'It is part of our philosophy to continuously look into innovations and new technologies and we are very happy to work with TeraView to offer our customers the emerging new Terahertz technology'.
http://www.laboratorytalk.com/news/tev/tev104.html
Thanks for the post.
I'm interested in Bruker's potential markets in follow on biologics. The biogeneric business is on the cusp of rapid growth and BRKR appears to be well situated as a toolmaker for biogeneric pharma. Here is an article I found interesting. Any comments?
FL
http://www.labtechnologist.com/news/ng.asp?n=77189-sandoz-momenta-pharmaceuticals-biogeneric-biosimi...
New high-resolution MRI machine comes to MIT
Cathryn M. Delude, News Office Correspondent July 31, 2007
Last May, MIT acquired its first 3 Tesla Siemens MRI machine for noninvasive imaging of the human brain, located in the Martinos Imaging Center at the McGovern Institute. This spring, a new, more powerful scanner moved in next to it, thanks to a gift from an anonymous donor. This scanner, a 9.4 Tesla Bruker magnet with a small (20 cm) bore, will be used for rodents and small primates, as well as live cell cultures and chemical preparations. It will help researchers make direct links between molecular and genetic techniques and live animal studies, and between animal studies and human studies.
"We're very grateful to our donor and to Bruker for helping bring this advanced imaging technology to all of MIT," said Robert Desimone, director of the McGovern Institute. "Now that the two MRI machines are just steps apart on our campus, we can move back and forth between human and animal studies much more easily. The 9.4T magnet will also be a new focal point for technology development on campus, including the development of new imaging agents."
Previously, researchers who wanted to work at this cutting-edge field strength had to carefully transport their experiments to the Charlestown campus of Massachusetts General Hospital (MGH) to conduct studies on a 9.4T machine there. Transportation was time-consuming and difficult, remembers Christopher Moore, a principal investigator in the McGovern Institute and assistant professor in the Department of Brain and Cognitive Sciences.
Getting the scanner to campus, and getting it up and running, has been a broad effort. Moore, working with Alan Jasanoff, an associate member of the McGovern Institute with appointments in nuclear science and engineering, biological engineering, and brain and cognitive sciences, did the groundwork in determining the specifications needed for making the machine maximally useful to the broader community while meeting the needs of each of their laboratories. In addition, many colleagues and collaborators at the Martinos Center at MGH helped train Moore and his laboratory in use of the 9.4T scanner, and provided invaluable help and advice in acquiring the scanner at MIT. Once the machine arrived, Steve Shannon and Christina Triantafyllou in the Martinos Imaging Center at the McGovern Institute, and other members of the Moore and Jasanoff laboratories, provided much of the expertise to put the machine on line. Moore will jointly oversee the MIT 9.4T scanner with Jasanoff.
After a trial period for the magnet throughout the summer, the scanner will be opened up to researchers in the community. "We hope it will facilitate a broad range of interdisplinary work in neurodegenerative diseases, systems neuroscience, developmental biology, cancer research, and new imaging technologies," Desimone says.
Tesla refers to the strength of the magnet, and the stronger the magnetic field, the finer the resolution of the image. The Martinos Imaging Center's 9.4T can resolve MRI signals down to 50 microns, smaller than the dot at the end of this sentence, and small enough to reveal differences among small clusters of neurons.
Researchers will mainly use the machine for live animal studies. For example, Moore will use it to investigate somatosensory processing in the primate brain. He has already demonstrated the magnet's power to pinpoint brain regions in New World monkeys never before known to be involved in tactile sensation. He was then able to determine that the analogous region of the human cortex also has this unsuspected function. Moore says this study exemplifies how animal studies can be used to gain new insights into the human brain. Moore is also preparing to use the powerful capability of this scanner to track blood in the brain, to test new hypotheses that vascular signals play a role in information processing.
For his animal studies, Jasanoff plans to focus on a classic paradigm of reward behavior in awake and behaving rats, examining patterns of neural activity across the entire brain. He is also collaborating with Susan Lindquist at the Whitehead Institute to do live imaging on mouse models for neurodegenerative diseases.
The scanner can also facilitate cellular, molecular and chemical studies, Jasanoff emphasized. For example, his laboratory is developing MRI contrast agents to apply to next-generation functional imaging, allowing him to observe neural functions with molecular specificity. He and his collaborators across MIT will use the 9.4T magnet to test properties of their newest imaging agents in cell and tissue culture. They have already developed an agent that detects calcium, which flows into cells as neurons fire, and are working on other indicator molecules for monitoring changes in neurotransmitters such as dopamine and serotonin, which are important for the control of motivation and emotion.
Jasanoff anticipates that researchers will integrate high-resolution MRI studies using the molecular imaging agents with a wealth of other imaging techniques, such as optical imaging in mouse models for human disease.
"New imaging tools are opening up the exploration of 'inner space' in the brain," Desimone said, "in much the same way that the telescope revolutionized our understanding of outer space."
http://web.mit.edu/newsoffice/2007/scanner-0731.html
Bruker BioSciences Corp.'s (BRKR) second-quarter net income climbed 96% to $4.96 million, or 5 cents a share, from $2.54 million, or 2 cents, a year earlier, boosted in part by new-product introductions.
The Billerica, Mass., parent company of Bruker AXS Inc., Bruker Daltonics Inc. and Bruker Optics Inc.'s revenue grew 21% to $121.7 million from $100.5 million, thanks in part to higher product and service revenue.
DOW JONES NEWSWIRES July 31, 2007
Bruker Mineralogical System Offers Simultaneous Detection and Analysis for All Elements Down to Boron - July 10, 2007
The successful integration of the world leading Quantax Esprit X-ray microanalyser software from Bruker AXS with the QEMSCAN® automated mineralogy system breaks new ground in advanced mineral analysis.
X-ray microanalysis is an analytical technique for precise determination of the chemical composition of solid samples, thin layers or particles under investigation in electron microscopes.
Intellection's QEMSCAN® is an advanced mineral analysis system based on technology pioneered by the Australian Commonwealth Scientific and Industrial Research Organisation (CSIRO) and in use around the world by geosciences laboratories in the Mining, Oil & Gas and Utilities sectors. QEMSCAN® is designed for unattended, high productivity analysis of minerals, rocks and materials.
As part of normal operation QEMSCAN® may detect compounds that require further analysis, often by an electron probe. Such analysis can cause delays and additional costs to the process of mineral analysis.
By integrating the liquid nitrogen free energy dispersive X-ray spectrometers (EDS) that are a standard part of QEMSCAN® and the Quantax Esprit software option it is possible to detect and analyze all elements down to boron simultaneously on the one QEMSCAN® instrument.
With true standardless analysis; proven standard related quantification; or even a combination of both methods, obtaining elemental information from a sample volume of only a few microns and providing relative detection limits in the order of a tenth of mass percent makes QEMSCAN® based Esprit X-ray microanalysis one of the most sensitive analysis methods available today.
Quantax Esprit is available immediately as an option for all QEMSCAN® systems using the Intellection X275HR Silicon Drift X-ray detectors.
http://www.azom.com/details.asp?newsID=9208
Bruker Edges Up After Upgrade
NEW YORK — Bruker BioSciences Corp., which makes X-ray technology and molecular analysis tools, rose Wednesday after an analyst upgraded the stock, saying a recent slide in share price has eliminated much of the risk in the stock.
Shares have fallen 22.2 percent since hitting a five-year high of $11.56 on April 30.
Noting that the stock was near his target price of $9, Bear Stearns analyst Stephen Unger upgraded the stock to "Peer Perform" from "Underperform." He said the company could exceed analyst estimates due to better sales at its optics business.
Unger sees little chance Bruker will miss his 2007 and 2008 profit estimates, which are significantly below other analysts' predictions. He forecast the Billerica, Mass.-based company to earn 20 cents per share this year, and 25 cents per share next year.
On average, analysts polled by Thomson Financial forecast a profit of 25 cents per share in 2007 and 31 cents per share in 2008.
Shares added 14 cents to $9.13 in afternoon trading Wednesday.
http://www.chron.com/disp/story.mpl/ap/fn/4925252.html
Bruker article in R&D Magazine (BRKR)
New Tools for Spectroscopy in the Life Sciences
New spectrometers and improvements to existing spectrometers enhance the quality of life science research.
The life sciences are but one of the areas which are benefiting from improved spectroscopy devices and methods. Proteomics, metabolomics, and biomarker profiling all use mass spectroscopy and will advance with these new products.
These new spectroscopy instruments and improvements have been introduced at various trade shows over the past few months. Indeed, at Pittcon 2007 in Chicago, Ill., spectroscopy products were the overwhelming favorites of the editors attending the conference, with spectrometers winning the majority of the Editors’ Choice Awards (see R&D Magazine, April 2007).
In addition to winning the Bronze Editors’ Choice Award for its ALPHA FT-IR spectrometer at Pittcon, Bruker Optics, Billerica, Mass., also added mid-IR capabilities with multiple fiber optic ports to its MATRIX series spectrometers. The new MATRIX-MF is a process ready FT-IR spectrometer that is ideal for real-time monitoring and analysis of chemical and biological reactions.
The MATRIX-MF is the smallest footprint FT-IR spectrometer with an automated built-in multiplexer. Up to 6 reactions can be monitored using a single instrument. The system uses the Bruker quick connector (BQC) design for easy and fast exchange of fiber optic probes. A wide range of probe adaptations, including Bruker’s new diamond ATR probe, can be attached to the unit for in situ analysis. An integrated MCT detector with a Stirling-cycle cooler s available for conditions in which continuous unattended operation is desirable or liquid nitrogen is not available.
Bruker BioSpin, Billerica, Mass., announced the Avance III NMR (nuclear magnetic resonance) spectrometer at Pittcon. It is a platform for life science and materials research, as well as a robust, automated, easy-to-use NMR analysis system for pharma/biotech, chemistry, metabolomics, nutritional science, and molecular diagnostics research.
The Avance III spectrometer is designed around an advanced digital concept that provides an optimized pathway for highest speed RF generation and data acquisition with a highly modular and scalable transmitter and receiver channel architecture. It also features a digital lock for experimental stability, and second-generation (2G-DR technology) for high dynamic range, high digital resolution, and large bandwidth digital filtering. The result is an extremely fast spectrometer with 25 ns event timing (12.5 ns clock), including simultaneous phase, frequency, and amplitude switching.
http://tinyurl.com/2x2rwb
Bruker Bears Have the High Ground
By Chris Schumacher
RealMoney.com Contributor
6/5/2007 8:34 AM EDT
Shares of Bruker BioSciences (BRKR - Cramer's Take - Stockpickr - Rating) fell off a cliff in early May, and the bears still have the upper hand. A look at the X-ray maker's technical picture shows a possible short-trade setting up.
The stock displayed strong price appreciation from February to April of this year. However, after Bruker met first-quarter targets, shares succumbed to a Bear Stearns' analyst report that the stock was overvalued.
Since that time, it appears that buyers have become more cautious. A capitulation phase like Bruker experienced in early May usually leads to a strong reversal that pushes the price back up to the point where shares were trading before the selling exhaustion.
In this case, this level equates to about $11.50. Instead, short-covering and reversal traders could only push the price back up to $9.40 before Bruker shares began forming a double bottom. The retest of the $8 support in late May shows that buyers are still willing to purchase weakness, but not strength.
It will take some time for the stock to build a base between $8 and $9.50, if the bulls in this life sciences company are to regain control of the daily chart.
Right now the stock's near-term support level at $8 is in danger of failing, which could lead to a further decline to the former $7 support. In order for the bulls to regain control of the daily chart, they will need to push the price back above $9.40 on a closing basis.
A close above $9.40 would likely cause the bears to cover their positions, and invalidate the developing short setup. But given the lower-volume reversal that occurred in May when the stock bounced off $8 and moved back up to $9, Bruker appears to have a higher probability of at least testing $8 again before climbing above $9.40 on a closing basis.
And if the bears prevail, shares could break even lower.
http://tinyurl.com/yrno7w
nice. I'm in her from 8.73 from yesterday. Glad to see she gave us nice buying support on that little selling yesterday.
Bruker (BRKR) Chairman Laukien buys 111,422 shares
May 8, 2007
SOURCE: Form 4
ISSUER: BRUKER BIOSCIENCES CORP
SYMBOL: BRKR
FILER: LAUKIEN FRANK H
TITLE: Chairman of the Board
DATE TRANSACTION SHARES PRICE VALUE
5/7/07 Purchase 111,422 $8.63 $961,238
OWNERSHIP: 19,361,760 (Direct)
The Form 4 is filed with the Securities and Exchange Commission by insiders to report transactions in their companies' shares. Open market purchases and sales must be reported within two business days of the transaction.
Bruker (BRKR) Chairman Laukien buys 7,500 shares
May 7, 2007
SOURCE: Form 4
ISSUER: BRUKER BIOSCIENCES CORP
SYMBOL: BRKR
FILER: LAUKIEN FRANK H
TITLE: Chairman of the Board
DATE TRANSACTION SHARES PRICE VALUE
5/4/07 Purchase 7,500 $8.84 $66,278
OWNERSHIP: 19,250,338 (Direct)
The Form 4 is filed with the Securities and Exchange Commission by insiders to report transactions in their companies' shares. Open market purchases and sales must be reported within two business days of the transaction.
Followers
|
2
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
106
|
Created
|
03/14/07
|
Type
|
Free
|
Moderators |
Bruker BioSciences Corp. (BRKR)
40 Manning Road
Billerica, MA 01821
USA
http://www.bruker-biosciences.com/index.html
http://www.brukeroptics.com/contacts/about.html
13.64 1/2/08
6.30 8/10/07
Shares Outstanding 105.5 Million
Float: 50.47 Million
Non-Corp. Insider Holdings: 52.10% (as of 12/1/07)
Institution Holdings: 49.10% (as of 1/1/08)
Total Held: 51.82 Million
Institutions: 134
41.8x P/E Ratio
0.26 EPS
________________________________________________________________________________________________________________________________
Bruker BioSciences Corporation designs, manufactures and markets analytical and life science systems and associated products.
It operates through three segments: Bruker AXS, Bruker Daltonics and Bruker Optics. Bruker AXS is a developer and provider of life science and advanced materials research tools based on X-ray technology tools for advanced X-ray and spark- optical emission spectroscopy (OES) instrumentation used in non-destructive molecular materials and elemental analysis in academic, research and industrial applications. Bruker Daltonics is a developer and provider of life-science tools based on mass spectrometry and also develops and provides a range of field analytical systems for chemical, biological, radiological and nuclear (CBRN) detection. Bruker Optics is a developer and provider of research, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technology. On July 1, 2006, it acquired Bruker Optics Inc.
________________________________________________________________________________________________________________________________
Latest News Headlines for Bruker BioSciences Corp
• Bruker Shareholders Approve Buyout AP (2.25.08 3:58pm)
• BRUKER BIOSCIENCES CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online (Mon 2:00pm)
• Bruker BioSciences approves merger, name change
bizjournals.com (Mon 11:36am)
• Bruker BioSciences Non-Affiliated Shareholders Overwhelmingly Approve Acquisition of Bruker BioSpin Group
Business Wire (Mon 10:49am)
• The Way to Prosperity
at Motley Fool (Mon 10:19am)
• Bruker BioSciences Corporation Earnings Call scheduled for Thu, Feb 28 CCBN (Sat, Feb 23)
• Bruker BioSciences Corporation to Release Fourth Quarter and Full Year 2007 Financial Results on February 28, 2008
Business Wire (Thu, Feb 21)
• Bruker AXS Buys JUWE Laborgeraete
AP (Mon, Feb 4)
• Bruker division closes on purchase of German firm
bizjournals.com (Mon, Feb 4)
• Bruker AXS Announces Closing of Acquisition of JUWE Combustion Analysis Business and Establishment of Elemental Analysis Center of Excellence
Business Wire (Mon, Feb 4)
________________________________________________________________________________________________________________________________
Weekly Charts
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |